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Abstract: Anemia, for which erythropoiesis-stimulating agents (ESAs) and iron supplements 
(ISs) are used as preventive measures, presents important difficulties for hemodialysis patients. 
Nevertheless, the number of physicians able to manage such medications appropriately is not 
keeping pace with the rapid increase of hemodialysis patients. Moreover, the high cost of ESAs 
imposes heavy burdens on medical insurance systems. An artificial-intelligence-supported 
anemia control system (AISACS) trained using administration direction data from experienced 
physicians has been developed by the authors. For the system, appropriate data selection and 
rectification techniques play important roles. Decision making related to ESAs poses a multi-
class classification problem for which a two-step classification technique is introduced. Several 
validations have demonstrated that AISACS exhibits high performance with correct 
classification rates of 72%–87% and clinically appropriate classification rates of 92%–98%. 
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1. Introduction 
Anemia, a common complication associated with chronic kidney disease (CKD), is a risk 
factor for high mortality [1]. Erythropoiesis-stimulating agents (ESAs) and iron supplements (ISs) 
are usually administered during hemodialysis treatment to patients. Generally, patients with 
large hemoglobin (Hb) variations are likely to have complications and often need to be 
hospitalized, and vice versa [2]. Therefore, physicians are trying to stabilize patients' Hb values 
within a certain range. However, doing so is very difficult because of complicated disorders such 
as altered iron metabolism, poor response to ESAs, and residual blood in dialysis equipment, 
which are mostly common problems for hemodialysis patients. Moreover, general situations such 
as concomitant diseases and differing backgrounds of patients in different countries [3,4] are also 
affecting the difficulty. Compounding these difficulties are economics concerns such as high costs 
of ESAs, which are heavily burdening medical insurance systems [5,6]. 
 Although hemodialysis patients are becoming increasingly numerous worldwide, 
physicians who are able to manage and administer treatment appropriately are not being trained 
in sufficient numbers to keep pace with the increasing numbers of patients requiring 
hemodialysis treatment [6]. To reduce burdens on physicians and medical insurance systems 
under these circumstances, effective decision-making support systems are urgently anticipated. 
Recently, artificial intelligence (AI) technologies have been used extensively in nephrology [7,8]. 
Several studies conducted to assess hemodialysis have predicted vital reactions including studies 
specifically examining anemia control [9–12]. Model predictive control (MPC) approach was 
utilized and extended for effective anemia control [10-12]. Systems using AI for predicting Hb 
values for hemodialysis patients were presented in the literature [13,14]. Anemia control model 
(ACM) achieved improved control accuracy and decreased patients’ need for ESAs [15,16]. 
Although anemia control assisted by AI technologies appears promising, a discrepancy persists 
between technologies and actual medical practice. Widely diverse health conditions of actual 
patients and various legal and economic constraints can cause many difficulties. As a result, 
available datasets including data of similar patients are usually not so large. Therefore, a different 
approach was adopted for AI learning in this study: the AI learns based on decisions of 
experienced physicians rather than data showing reactions of the patients’ living bodies, such as 
Hb values. From highly experienced physicians with work histories including blood examination, 
we gathered data of their dosage direction decisions for patients there. To enhance the learning 
process, we constructed procedures for the rectification of clinical data. Then we developed an 
artificial-intelligence-supported anemia control system (AISCAS). 
2. Materials and Methods 
2.1 Patients and datasets 
2.1.1 Ethics statement 
Clinical data were collected retrospectively from electronic health records. This study, which 
was conducted in accordance with the Declaration of Helsinki, was approved by the institutional 
review board (IRB) at Shigei Medical Research Hospital (#20161219-1) and Kobayashi Medical 
Clinic (#20190925), as a retrospective observational study. The endpoint of this study approved 
at IRBs was to construct a decision-making support system that can provide dosage directions 
that are equal to or better than those of physicians who control dosages to maintain hemoglobin 
(Hb) values within 10–12 g/dl: the criterion stated in the Japanese hemodialysis guideline. 
2.1.2 Clinical data collection 
Clinical data were collected at two hospitals where Japanese adult hemodialysis patients 
were receiving anemia control treatment by board-certified senior members of the Japanese 
Society for Dialysis Therapy. Data were collected at Shigei Medical Research Hospital (Hospital 
S) from January 2015 through May 2019 and at Kobayashi Medical Clinic (Hospital K) from 
November 2018 through September 2019. All clinical data were anonymized. At Hospital S, the 
S1 and S2 datasets were prepared. Dataset S1 was used for training the neural network; S2 was 
used for raw data validation. At Hospital K, dataset K1 was prepared and used for raw data 
validation. At both hospitals S and K, directions by physicians at every hemodialysis occasion, 
which are every one or two weeks depending on the hospitals, were recorded in the form of UP, 
DOWN, or STAY because dosages for administration were directed in units of one ampoule 
under hospital regulations. The hemodialysis patients were 350 per year at Hospital S and 90 per 
 year at Hospital K. The cases of mortality were 35 per year at Hospital S and 10 per year at 
Hospital K. Hospital K was selected to examine the applicability of AISACS at smaller hospitals. 
The patient selection criteria were the following: maintenance hemodialysis, no concomitant 
inflammation (CRP<0.3 mg/dL), no infectious disease, and no present cancer. Moreover, the data 
collection period for each patient case was chosen to include as many UP and DOWN directions 
as possible in both training and validation groups. This period-selection criterion was used 
because data for maintenance hemodialysis patients in stable condition include larger numbers 
of STAY directions than either UP or DOWN directions, indicating that appropriate timings of 
UP and DOWN decisions are significant for patient care. 
As a result obtained from data selection criteria described above, dataset S1 with N=130, 
W=6080, and dataset S2 with N=81, W=1857 were prepared from Hospital S, where N and W 
respectively represent the number of patients and hemodialysis occasions. Dataset S1 was used 
for training the neural network, whereas S2 was used for raw data validation. Dataset K1 was 
prepared and used for raw data validation with N=16 and W= 298. 
Darbepoetin alfa and epoetin beta pegol were used as ESAs. The ISs were provided in the 
form of sodium ferrous citrate, ferrous fumarate, and saccharated ferric oxide (Supplemental 
Table A1). The target range was set as 10.0–12.0 g/dl at Hospital S according to the Japanese 
hemodialysis guideline. The Hb values were controlled by physicians within target ranges of 74% 
in S1 and 73% in S2 (Supplemental Table A2). Also, ESA-resistant patients were excluded. 
Therefore, the mean administered dosages of darbepoetin alfa were 20.2±10.1 µg/week in S1, 
18.8±14.1 µg/week in S2 and 20.4±13.5 µg/week in K1. The mean administered dosages of epoetin 
beta pegol were 26.1±8.9 µg/week in S1, 36.0±15.7 µg/week in S2, with no use in K1 (Supplemental 
Table A3). 
2.1.3 Inputs and outputs for machine learning 
Four items of blood examination were regarded as neural network inputs: Hb; mean 
corpuscular volume (MCV); ferritin; and transferrin saturation (TSAT). These items, their trends, 
and histories of dosages for ESAs and ISs up until the previous administration occasion were 
used as input parameters. Finally, AISACS outputs probabilities for ternary directions in the form 
of UP, STAY, and DOWN in ESAs, and UP and STAY for binary directions in ISs, as shown in 
Figure 1. Ternary directions were not needed for ISs because the ISs were set to stop after 6 weeks, 
in accordance with hospital regulations. 
 
 
 
 
 
 
 
 
Figure 1. Inputs and outputs for machine learning. 
2.1.4 Data rectification 
One important difficulty in collecting administered dosage data is posed by “delayed 
decisions.” For each hemodialysis occasion, patients underwent blood examinations. Usually the 
physicians then examined the results and gave administration directions. However, not all the 
decisions were made on the same day of the examination because of the delays in delivering the 
 examination results to physicians caused by mechanical troubles, working time restrictions, and 
other factors. In such cases, the decision events were actually recorded with a week delay after 
the blood examination results on which the decision was actually based. Such a non-essential 
difference between blood examination and decision dates confused the neural network training 
process considerably. Therefore, we performed data rectification by moving the UP and DOWN 
decision dates to the exact dates on which the blood examinations were actually performed. This 
rectification procedure was done automatically and was confirmed by three physicians. The 
procedure was applied only for S1 to be used for neural network training. 
2.2 Machine learning and validations 
2.2.1 Preliminary analyses 
Before starting a deep learning approach, we applied simpler approaches to examine the 
complexity of our classification problem. Figure 2 portrays a principal component analysis (PCA) 
based on input data. From Fig. 2 using three principal components (PCs), it is apparent that 
almost all UP and DOWN decisions were readily classifiable using linear approaches, but UP and 
STAY, or STAY and DOWN are difficult to classify clearly using PCs. Moreover, several outliers 
exist, such as UP decisions located in the upper-right corner of Fig. 2(b). Based on these 
preliminary attempts, we decided to apply a deep learning approach, which is expected to work 
for such nonlinear, high-complexity classification problems. 
Figure 2. Classification by principal component analysis. 
2.2.2 Machine learning setup 
Machine learning codes were written using Keras with a TensorFlow backend [17,18]. The 
blood examination intervals for Ferritin/TSAT are usually longer than that of Hb/MCV. Therefore, 
we used independent neural networks of two kinds for the two forms of medication. Indeed, Hb 
and MCV are examined every week, whereas Ferritin and TSAT are examined every month, 
which means that only a quarter of the dataset has actual measured values of Ferritin and TSAT 
to predict ISs. For this reason, whereas a dense neural network was used for ESAs, a recurrent 
neural network (RNN) [19] was used for ISs as a more effective method when fewer data are 
available. Considering the tradeoff between training data size and representation ability, a 
recursive layer with sequence size two was added to the dense neural network, so two successive 
timings are passed as inputs. Both networks used 10 hidden layers with L1 regularization and 
 drop-out techniques [22] to prevent overfitting phenomena. Other training parameters and 
hardware used for machine learning are presented in Table 4A. 
2.2.3 Validations 
We defined correct classification rates RTOTAL as 
 𝑅TOTAL = number of correct decisionsnumber	of input decision data, 
 
which were the ratios by which AISACS gave the same directions on the same dates as those 
given by physicians. We also defined RUP, RSTAY, and RDOWN by confining the decision to each class. 
Using these values, we performed the following validations of two types. 
 
• “Leave one patient out” cross-validation (LOPO) 
LOPO was performed by removing data of one patient from the dataset. The neural 
network was trained using the remaining N-1 patient data. Then the removed patient data 
were used to evaluate the performance of the trained neural network. After repeating this 
procedure N times, correct classification rates were calculated using N patients results. The 
S1 dataset was used for LOPO. 
 
• Raw data validation (RDV) 
RDV was performed using S2 and K1. First, we trained the neural network using S1. Then 
the correct classification rates were calculated using S2 (RDV_S) and K1 (RDV_K). Training 
and validation processes are completely independent in RDV_S and RDV_K. 
 
Validations performed in this study are presented in Table 1 and are shown schematically in 
Figure 3. 
Table 1. Validations and datasets using S1 and S2 from Hospital S and K1 from Hospital K. 
Name Validation procedure Dataset for training Dataset for validation 
LOPO Leave one patient out cross-validation S1 
RDV_S Raw data validation S1 S2 
RDV_K Raw data validation S1 K1 
  
Figure 3. Leave one patient out (LOPO) cross-validation and raw data validations (RDV) procedures. 
2.2.4 Class-imbalanced training data 
Although we selected the clinical data period that includes plentiful UPs and DOWNs, the 
numbers of different directions included in the dataset are still markedly imbalanced. For 
example, in dataset S1, ESA directions by physicians comprised 344 UPs, 585 DOWNs, and 5151 
STAYs. Simple machine learning using such an imbalanced dataset led to AI always outputting 
the STAY direction to achieve the highest RTOTAL. However, the timings of UP and DOWN are 
much more important for the present problem. Such a discrepancy can usually be controlled by 
class weights, respectively strengthening and weakening the effects of minority and majority 
classes on the target functions. Although values of class weights are usually defined using the 
inverse ratios of quantities of data, class-imbalance was not improved sufficiently for AISACS. 
Therefore, they were further adjusted to strengthen minority classes by trial and error so that 
RUP, RSTAY, and RDOWN are approximately equal in S1. 
2.2.5 Two-step classification for the ternary classification for ESAs 
Because the ESA administration belongs to ternary classification problems, three probability 
values of PUP, PSTAY, and PDOWN, respectively corresponding to UP, STAY, and DOWN directions, 
were computed as outputs from the neural network. The simplest method for classification is to 
adopt a direction that gives the highest probability value. However, such a simple algorithm does 
not seem to work for the present situation in which the timings of UP and DOWN are crucially 
important to appropriate anemia control. Therefore, we propose the following procedure for the 
ternary classification problem: First, we set a threshold value T. The direction is assigned as STAY 
if the probability of STAY was larger than T. Otherwise, UP or DOWN, which has a larger 
probability, is assigned, as portrayed in Fig. 4. We designate the union of UP and DOWN classes 
as NON-STAY in the following sections. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Flow chart of two-step classification for ESAs. 
3. Results 
3.1 Classification between STAY and NON-STAY directions 
As described in 2.2.1, assigning classification for ESA administration between STAY and NON-
STAY directions is much more difficult than assigning classification between UP and DOWN directions. 
Therefore, we examined the classification ability of AISCAS by drawing receiver operating characteristic 
(ROC) curves for STAY and NON-STAY directions by changing the threshold T. Figure 5 portrays ROC 
curves and area under curve (AUC) values for ESAs and ISs. Threshold T is varied from 0 to 1. For ESAs, 
RDV_K shows lower AUC than RDV_S, which can be a consequence of the fact that AISCAS was trained 
using data from Hospital S. This point is discussed in Section 4.  
Figure 5. ROC curves and AUC values for ESAs and ISs. 
3.2 Correct classification rates after fixing threshold T 
On actual situations in hospitals, a threshold value T discussed in 2.2.4 should be decided. 
One possible strategy using the ROC curves is to choose T corresponding to the nearest point on 
the ROC curve from point (x, y) = (0, 1) to achieve similar abilities for both STAY and NON-STAY. 
For dataset S1, this value appeared to be 0.475 for ESAs and 0.470 for ISs, which we adopted also 
for validations and which gives the correct classification rates RTOTAL for LOPO, RDV_S, and 
RDV_K as 80%, 77%, and 72% for ESAs and 81%, 87%, and 80% for ISs. 
 3.3 Examining incorrect classification cases 
To analyze reasons for incorrect classification cases, we reviewed them carefully one-by-one, 
which revealed some directions by AISACS that appeared to be appropriate from a medical 
perspective, even though they differed from the physician’s recorded directions. We defined 
these as “clinically appropriate” directions. Moreover, we found that a characteristic type exists 
in “clinically appropriate” directions, which we defined as a “before physician” direction. In 
“before physician” directions, AISACS gave the same UP or DOWN directions with physicians, 
but gave it a week or so earlier than the physician did. “Before physician” directions are calculable 
automatically by counting up to three earlier administration occasions than the physician. 
Although such “before physician” directions are counted as incorrect classifications in 3.2, they 
portray an interesting feature of AISACS. Other “clinically appropriate” directions are the other 
portion in clinically appropriate directions judged by board-certified doctors. The rate of “before 
physician” in validations LOPO, RDV_S, and RDV_K were, respectively, 9%, 7%, and 8% for 
ESAs and 5%, 5%, and 5% for ISs. The rate of “clinically appropriate: other” directions were, 
respectively, 8%, 8%, and 15% for ESAs and 9%, 6%, and 10% for ISs. Ratios for “correct 
classification,” “clinically appropriate: before physician,” and “clinically appropriate: other” are 
shown respectively in Figs. 6 and 7. 
Figure 6. Categorization of classification results by AISACS for ESAs with T=0.475. 
 
Figure 7. Categorization of classification results by AISACS for ISs with T=0.470. 
Finally, gross rates of appropriate directions, which were the sum of “correct classification,” 
“clinically appropriate: before physician,” and “clinically appropriate: other,” in validations 
LOPO, RDV_S, and RDV_K were 97%, 92%, and 95% for ESAs and 95%, 98%, and 95% for ISs.  
4. Discussion 
Four features of AISACS are particularly important. The first feature is what AI learns: reactions 
of living bodies or decisions of experienced physicians. Systems for predicting future Hb values 
 of maintenance hemodialysis patients using AI technology have been reported as described in 
Section 1. We adopted a different approach by which AI learns from experienced physicians’ 
dosage directions. Actually, experienced physicians do not calculate detailed values of vital 
reactions when deciding dosages. We selected five items of blood examination, their trends, and 
dosage histories as inputs by looking at the judgments reported by physicians. 
A second feature is proper data selection and rectification. For example, “delayed decisions” 
appear frequently in real datasets because of mechanical difficulties and working time restrictions. 
In such cases, the decision dates were recorded with a one or two week lag after the blood 
examination actually occurred. Such a nonessential difference between blood examination and 
actual decision dates confuse the training process of our neural network considerably. Therefore, 
we moved the dates of UP and DOWN directions to dates on which the decisions were actually 
based. Such a data rectification procedure functioned well to make the training process efficient, 
even though the training in this study was based on a small sample of data. Figure 8 presents 
correct classification rates for ESAs in S1 improved during AISACS development: in (a) with a 
few layers in a neural network with no weighting techniques, it almost always yields the STAY 
direction. Then, by a tuning of class weights, the correct classification rates RUP, RSTAY, and RDOWN 
became approximately equal to each other as portrayed in Fig. 8(b). By increasing the number of 
layers and by adding several means from (c)–(e) such as class weights, dosage histories reference 
and two-step classification, the correct classification rates, especially for UP and DOWN, were 
improved considerably. 
 
 
 
 
 
 
Figure 8. Correct classification rates for ESAs in S1 during developing AISACS. 
When comparing the AUCs in raw data validation using data from hospitals S and K (RDV_S vs. 
RDV_K), the AUC from RDV_S was found to be higher than that from RDV_K because AISACS 
was trained using the dataset from Hospital S. Apparently, AISACS has some affinity to 
physicians at Hospital S. However, the “clinically appropriate” rates for Hospital K were 
sufficient, which suggests that AISACS has a certain degree of flexibility. 
A third feature is the multi-class classification for ESAs. The direction timings of UP and 
DOWN are crucially important for appropriate anemia control. Therefore, we set a threshold 
between STAY and NON-STAY directions using the ROC curve based on probabilities calculated 
using the neural network. Then, NON-STAY is classified to UP or DOWN simply by comparison 
of their probabilities. It is possible to tune the frequency of decision changes by adjusting the 
threshold value. For example, if the threshold were set at a higher value, then AISACS would 
give more frequent UPs and DOWNs. This feature might be useful when AISACS is applied at 
different hospitals. 
A fourth feature is that AISACS sometimes shows better timing than physicians for changing 
dosage directions as described in Section 3.3. The appearance of “before physician” directions 
 portrays an interesting feature of AISACS, which can contribute to helping physicians to see right 
timings to increase or decrease dosages. There is an additional interesting point here. As 
presented in Section 3.1, the AUC value from RDV_K for ESAs was quite lower than that from 
RDV_S, which might be attributable to AISACS learned decisions of physicians at Hospital S. 
However, many of the incorrect classification cases were regarded as clinically correct through 
multiple doctors’ reviews. Actually, on one hand, the AUC of RDV_K for ESAs is the lowest 
among four raw data validations. On the other hand, the “clinically appropriate decision” portion 
of it was the highest. 
The present study has the following limitations. We conducted retrospective analysis for 
patients from only two hospitals, involving only Japanese patients with a small sample size. 
Moreover, we did not evaluate the cost of ESAs and irregular cases such as patients with 
conditions aggravated by other diseases. Considering the endpoint approved at IRBs for this 
study, it is difficult at the moment, to ascertain whether AISACS can give better directions than 
physicians, or not. A prospective, multi-center study is therefore needed, especially for 
confirmation of patient safety. 
5. Conclusions 
Preventing anemia is important to improve the prognosis and quality of life of hemodialysis 
patients. However, the pathophysiology associated with anemia is complicated. It requires a 
great deal of experience to control anemia cases adequately. The number of such physicians is 
insufficient. For this reason, we have constructed AISACS. The challenges and contributions to 
anemia control practices described in this paper are the following. 
• Not-so-large training dataset: We have constructed proper data selection and rectification 
procedures that play important roles in enhancing machine learning efficiency with small 
datasets. 
• Importance of appropriate timing of dosage changes: AISACS provides ternary directions for 
ESAs equipped with a threshold value to control NON-STAY and STAY decision tendencies.  
• Widely diverse health conditions of dialysis patients: Patients have several legal and economic 
constraints. A feature that is unique to AISACS is that it learns dosage directions from 
physicians using no prediction model based on biochemistry or physiology. 
 
In addition, an interesting feature of AISACS is that it sometimes produces “clinically appropriate” 
directions that are different from those of physicians, but which are nonetheless proper. Finally, 
AISACS has achieved a quite high gross rates of correct classification, which means giving the 
same direction with physicians on the same date, as 72%–87% and clinically appropriate 
classification, although it includes different decisions from those of physicians as 92%–98% 
through several validations. These results attest to AISACS’ promising possibilities for clinical 
applications after wider validation through a prospective, multi-center study. 
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 Appendix A 
Table A1. Background 
 Hospital S Hospital K 
 S1 S2 K1 
 (N=130) (N=81) (N=16) 
Sex    
Male 78 49 9 
Female 52 32 7 
Age (years)    
Mean 78.0 65.6 68.3 
Range 26–89 35–84 51-86 
Hemodialysis period    
Mean 9.7 11.9 3.5 
Range 1–42 1–35 1-11 
Primary disease    
Chronic glomerulonephritis (CGN) 62 49 2 
Diabetes 32 19 8 
Renal sclerosis 15 10 3 
Cystic kidney 8 0 0 
Ureteral stone 1 0 0 
Other 12 3 3 
Erythropoiesis-stimulating agent    
Darbepoetin alfa 121 68 16 
Epoetin beta pegol 9 11 0 
No administration 0 2 0 
Iron supplement    
Sodium ferrous citrate 32 22 1 
Ferrous fumarate 5 4 0 
Saccharated ferric oxide 50 26 11 
Sodium ferrous citrate 
 + Saccharated ferric oxide 
8 7 0 
No administration 35 22 4 
Table A2. Ranges of blood examination dataset 
 Dataset Examination item Start End 
 Hospital S 
S1 (N=130) 
Hb (g/dl) 10.3±0.8 10.8±0.6 
MCV (fl) 89.6±7.3 92.5±5.3 
TSAT (%) 21.6±11.4 31.7±29.6 
Ferritin (ng/ml) 53.7±50.3 72.7±46.7 
S2 (N=81) 
Hb (g/dl) 10.5±0.8 10.9±0.9 
MCV (fl) 92.0±7.0 92.6±6.1 
TSAT (%) 21.7±10.0 26.8±14.1 
Ferritin (ng/ml) 52.6±37.8 61.8±41.3 
Hospital K K1 (N=16) 
Hb (g/dl) 11.1±0.7 10.9±0.7 
MCV (fl) 93.8±5.7 95.3±4.5 
TSAT (%) 23.2±10.1 23.4±6.4 
Ferritin (ng/ml) 50.1±31.9 34.8±14.0 
Table A3. Mean ESAs administered dosage 
  Darbepoetin alfa Epoetin beta pegol 
Hospital S 
S1 (N=130) 
20.2±10.1 µg/week 
(N=120) 
26.1±8.9 µg/2 weeks 
(N=10) 
S2 (N=81)  
18.8±14.1 µg/week 
(N=68) 
36.0±15.7 µg/2 weeks 
(N=11) 
Table A4. Training parameters and a hardware for machine learning 
Parameter Setting 
Number of units in each layer 512 
Drop-out 20% 
Regularization coefficient 0.3 
Optimization method Adam method 
Number of inputs 16 
Number of outputs ESAs, 3; ISs, 2 
Number of epochs 1000 
Hardware 
iMac with CPU: Intel4I Core I7, 
RAM: 32GB, GPU: AMD Radeon R9 M395X 
CPU time for one training Approximately 600 s 
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